To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Parkinson's Disease
Interventions
DRUG

AZD3241 ER formulation 1

Oral tablets, 100mg bd on Day 1 to Day 2, 200mg bd on Day3, 300mg bd on Day 4 to Day7 and 300mg Once daily on Day 8 with High Fat Breakfast

DRUG

Placebo

Placebo will be administered with the same intervention scheme as intervention 1 and 2

DRUG

AZD3241 Alternative titration scheme with formulation 1 or 2

50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8

Trial Locations (1)

Unknown

Research site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY